Company: MDCXW
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001062993-25-007073
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-04
Form: POS AM
Chunk 14
---
                                                                                                  |
| Use of Proceeds    | We intend to use the net proceeds from cash exercises of the Public Warrants, if any, to fund our Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using our doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use any net proceeds to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin diseases. We will use any remaining net proceeds for general corporate purposes and working capital. See "Use of Proceeds."                                             |
| Voting rights      | Each outstanding common share will be entitled to one vote on all matters submitted to a vote of shareholders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Listings           | Our common shares and Public Warrants are listed on the Nasdaq under the symbols "MDCX" and "MDCXW," respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dividend policy    | We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. |
| Risk factors       | See "Risk Factors" and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                               |

Except as otherwise noted, all information contained in this prospectus assumes no exercise of our outstanding options (as described herein) or Warrants.

<div align='center'>-7-

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus.

We have derived the selected consolidated statement of operations for the years ended December 31, 2024 and 2023 and the selected consolidated balance sheet information as of December 31, 2024 and 2023 from our audited consolidated financial statements included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance